Hemoglobins Or Globins Patents (Class 530/385)
  • Patent number: 9493616
    Abstract: The present invention relates generally to methods for preparing polyethylene glycol (“PEG”) conjugated hemoglobin (“Hb”) using reduced reactant ratios. More specifically, the present invention relates to methods for preparing PEG conjugated Hb (“PEG-Hb”) with enhanced yield and purity.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: November 15, 2016
    Assignee: Sangart, Inc.
    Inventors: Ashok Malavalli, Kim D. Vandegriff
  • Patent number: 9403863
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, provided herein are compounds according to Formula I: or a pharmaceutically acceptable salt, solvate, tautomeric or polymorphic form thereof.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: August 2, 2016
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Dominique Surleraux, Cyril B. Dousson, Gilles Gosselin, David Dukhan, Claire Pierra, Jerome Peyronnet
  • Patent number: 9062097
    Abstract: The present invention relates to methods for the formation of inter-molecular disulphide bonds, including (poly)peptides/proteins, nucleic acids, vectors, host cells and bacteriophages used in these methods. Furthermore the invention relates to the use of this method for the improved display of (poly)peptides/proteins on the surface of bacteriophage particles.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: June 23, 2015
    Assignee: Morpho Sys AG
    Inventors: Josef Prassler, Yvonne Stark
  • Patent number: 9056098
    Abstract: The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1 ?, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: June 16, 2015
    Assignee: VISION GLOBAL HOLDINGS LTD.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Sze Hang Lau
  • Patent number: 9028801
    Abstract: The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 12, 2015
    Assignees: Electrophoretics Limited, Medical Research Council, University College London
    Inventors: Malcolm Andrew Ward, John Collinge, Graham Stuart Jackson, Emma McGregor, Nicola Louise Leeds, James Campbell, Jules Arthur Westbrook, Helen Louise Byers
  • Publication number: 20150094267
    Abstract: The present invention relates to succinimide-activated nitroxyl compounds and methods for the synthesis of such compounds. The present invention also relates to the use of succinimide-activated nitroxyl compounds to prepare nitroxylated proteins, for example nitroxylated heme proteins (e.g., nitroxylated hemoglobin and nitroxylated myoglobin). The nitroxylated proteins are optionally also conjugated to a polyalkylene oxide (PAO), for example to a polyethylene glycol (PEG). Polynitroxylated heme proteins are useful as oxygen therapeutic agents (OTAs). The invention further relates to pharmaceutical compositions of the nitroxylated proteins and methods for the use of nitroxylated proteins in the treatment of various conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 2, 2015
    Inventors: Kim D. Vandegriff, Ashok Malavalli, Gnel Mkrtchyan
  • Publication number: 20150087590
    Abstract: PEGylated diaspirin-crosslinked hemoglobin conjugates having high oxygen affinity are described which have enhanced nitrite reductase activity to deliver oxygen, carbon monoxide, nitric oxide or mixtures thereof to tissues to treat various diseases and conditions.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 26, 2015
    Inventors: Kim D. Vandegriff, Ashok Malavalli, Scott D. Olsen
  • Publication number: 20150079658
    Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.
    Type: Application
    Filed: November 21, 2014
    Publication date: March 19, 2015
    Inventors: J Milton HARRIS, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Francesco Maria Veronese, Tacey Viegas, Anna Mero
  • Publication number: 20150050713
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: July 25, 2014
    Publication date: February 19, 2015
    Inventors: Michael P. Malakhov, Fang Fang
  • Patent number: 8889830
    Abstract: A novel hemoglobin-albumin complex which has high stability of the oxygenated form, has high biocompatibility, and is easily prepared (synthesized), and an artificial plasma expander and an artificial oxygen carrier containing the complex are provided. The hemoglobin-albumin complex of the invention is characterized by having hemoglobin as the core, and albumin as the shell bound via a crosslinker to the above hemoglobin. Also, the artificial oxygen carrier of the invention is characterized by containing the hemoglobin-albumin complex of the invention.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: November 18, 2014
    Assignee: Chuo University
    Inventors: Teruyuki Komatsu, Daiki Tomita
  • Publication number: 20140335018
    Abstract: The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
    Type: Application
    Filed: May 13, 2014
    Publication date: November 13, 2014
    Applicant: Vision Global Holdings Ltd.
    Inventors: Bing Lou WONG, Norman Fung Man WAI, Sui Yi KWOK, Man Kin WONG, Cornelia Wing Yin MAN
  • Publication number: 20140323403
    Abstract: A modified hemoglobin oxygen transport agent useful in the treatment of hypoxia and related conditions is disclosed. The composition consists primarily of carbohydrate shielded hemoglobin or a hybrid hemoglobin molecule to deliver oxygen in hypoxia stage. The carbohydrate shielded hemoglobin therapy is based on oxidation physiology, which is believed to play key roles in ischemia, anemia and other conditions related to hypoxia.
    Type: Application
    Filed: December 8, 2011
    Publication date: October 30, 2014
    Inventor: David Platt
  • Publication number: 20140308260
    Abstract: The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 16, 2014
    Inventors: Bryan T. Oronsky, Jan Scicinski, Susan Knox, William Fitch, Frans A. Kuypers, Marcel Fens, Sandra Larkin, Pedro Cabrales, Chad Brouse
  • Patent number: 8853361
    Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation com
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: October 7, 2014
    Assignee: Khorionyx
    Inventor: Jean-Louis Tayot
  • Publication number: 20140255477
    Abstract: While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body.
    Type: Application
    Filed: April 25, 2014
    Publication date: September 11, 2014
    Applicant: VINDICO NANOBIO TECHNOLOGY INC.
    Inventor: P. Peter GHOROGHCHIAN
  • Publication number: 20140256636
    Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.
    Type: Application
    Filed: May 20, 2014
    Publication date: September 11, 2014
    Applicant: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Seetharama A. Acharya, Belur N. Manjula
  • Publication number: 20140171360
    Abstract: A nutritional supplement, a method for increasing the bacterial mass in the rumen of a ruminant and a nutritional preparation and corresponding uses. A nutritional supplement including proteins with a degree of hydrolysis above 28% and/or which have more than 23 mg ?-amino nitrogen per gram of protein and/or have more than 10% of free amino acids. The hydrolyzed proteins are animal proteins, preferably hemoglobin. The supplement is supplied orally, included in a nutritional preparation, in liquid, concentrated or dehydrated form.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 19, 2014
    Applicant: APC EUROPE S.A.
    Inventors: Francisco Javier Polo Pozo, Carmen Rodriguez Canel, Alejandro Bach Ariza, Anna Aris Giralt
  • Patent number: 8742073
    Abstract: A high temperature-stable and highly purified ?-? cross-linked tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells obtained from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents the lysis of white blood cells. Nucleic acids from white blood cells and the phospholipids impurities are not detected. The blocking of reactive sulfhydryl groups in hemoglobin by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography is used to remove different plasma protein impurities. N-acetyl cysteine is added to the ?-? cross-linked tetrameric hemoglobin solution to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: June 3, 2014
    Inventors: Bing Lou Wong, Sui Yi Kwok
  • Patent number: 8703143
    Abstract: According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also provides materials and methods for the production of such binding members.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 22, 2014
    Assignee: Philogen S.p.A.
    Inventors: Dario Neri, Barbara Carnemolla, Luciano Zardi, Gregory Paul Winter
  • Publication number: 20140106004
    Abstract: The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1?, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.
    Type: Application
    Filed: December 13, 2012
    Publication date: April 17, 2014
    Inventors: Bing Lou WONG, Norman Fung Man WAI, Sui Yi KWOK, Sze Hang LAU
  • Patent number: 8697645
    Abstract: Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin are additionally provided, as are methods of making a hemoglobin. Pharmaceutical compositions and blood substitutes using these hemoglobins are further provided, as are methods of treating a subject using these pharmaceutical compositions and blood substitutes.
    Type: Grant
    Filed: March 12, 2008
    Date of Patent: April 15, 2014
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Seetharama A. Acharya, Belur N. Manjula
  • Publication number: 20140099696
    Abstract: Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    Type: Application
    Filed: April 30, 2013
    Publication date: April 10, 2014
    Applicant: Ansun Biopharma, Inc.
    Inventors: Michael P. Malakhov, Fang Fang
  • Publication number: 20140094411
    Abstract: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: April 3, 2014
    Applicant: CSL Behring LLC
    Inventor: CSL Behring LLC
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Publication number: 20140087965
    Abstract: The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicants: SNU R&DB FOUNDATION, LG ELECTRONICS INC.
    Inventors: Yunhee KU, Youngsoo KIM, Seungyeon SONG, Jonghwa JIN, Moosub KIM, Yongju YANG
  • Publication number: 20140065170
    Abstract: The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.
    Type: Application
    Filed: September 17, 2013
    Publication date: March 6, 2014
    Applicant: A1M Pharma AB
    Inventors: Stefan Hansson, Bo Akerström
  • Publication number: 20140046027
    Abstract: The present invention concerns a method of modifying the surface of a cellulosic material, wherein a modifying compound is attached to the cellulosic material through a linker, which linker is a conjugate that has been activated by functionalization prior to adsorption to form an activated conjugate, and wherein the entire method is carried out in aqueous media, as well as an intermediate product suitable for attaching to a modifying compound, the intermediate product comprising said functionalized conjugate linker that has been adsorbed to a cellulosic material.
    Type: Application
    Filed: March 7, 2012
    Publication date: February 13, 2014
    Applicant: AALTO UNIVERSITY FOUNDATION
    Inventors: Janne Laine, Sami Nummelin, Eero Kontturi, Olli Ikkala, Ilari Filpponen, Henna Rosilo
  • Patent number: 8609814
    Abstract: The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: December 17, 2013
    Assignee: University of Essex Enterprises Limited
    Inventors: Christopher Eric Cooper, Michael Thomas Wilson, Brandon Jon Reeder
  • Patent number: 8609815
    Abstract: The present invention is a method for preparing stable HBOC solutions. Specifically, the method comprises the steps of deoxygenating a PEG-Hb conjugate and adding one or more antioxidants during or following the deoxygenating step to form a stabilized PEG-Hb conjugate. The Hb in the PEG-Hb conjugate is not crosslinked and the stabilized PEG-Hb conjugate has a p50 less than that of native SFH from the same animal source when measured under the same conditions. Specifically, the p50 is 6±2 mmHg or less than 10 mmHg.
    Type: Grant
    Filed: September 1, 2011
    Date of Patent: December 17, 2013
    Assignee: Sangart, Inc.
    Inventors: Kim D. Vandegriff, Ashok S. Malavalli
  • Patent number: 8603828
    Abstract: Hemoglobin, its variants, and glycated forms of each are determined individually in a multiplex assay that permits correction of the measured level of HbA1c to account for glycated variants and other factors related to the inclusion of the variants in the sample. New antibodies that are particularly well adapted to the multiplex assay are also provided.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 10, 2013
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Roger Walker, Benedicte Jardin
  • Patent number: 8580929
    Abstract: The present invention concerns a novel retinoic acid regulated gene whose expression product displays useful morphogenic/mitogenic properties. The present invention further concerns an isolated nucleic acid of SEQ ID NO:1 encoding a retinoic acid regulated expression product having an amino acid sequence of SEQ ID NO:2.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: November 12, 2013
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Y. Ip, William M. W. Cheung
  • Publication number: 20130288949
    Abstract: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 31, 2013
    Inventors: Robert M. Winslow, Kim D. Vandegriff
  • Patent number: 8551536
    Abstract: This disclosure relates to methods of using nitrite to detoxify stroma-free hemoglobin based blood substitutes. In particular, methods are described for using a blood substitute comprised of about equimolar amounts of nitrite and hemoglobin (e.g., nitrite-metHb) to treat, prevent, or ameliorate diseases of the blood in a subject, or as a blood replacement in a subject.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: October 8, 2013
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Alabama at Birmingham, Wake Forest University
    Inventors: Mark T. Gladwin, Daniel B. Kim-Shapiro, Rakesh P. Patel, Jeffrey Kerby
  • Patent number: 8546546
    Abstract: An antibody that binds to Mucin17 (Muc17) is disclosed. The antibody of the present invention preferably binds to the peptide of SEQ ID NO:3 and does not bind to the peptide of SEQ ID NO:4 or the peptide of SEQ ID NO:5. Also disclosed are an anti-cancer agent, preferably an anti-cancer agent for pancreatic cancer, which comprises the antibody of the present invention, as well as a method of diagnosing cancer using the antibody of the present invention, preferably the antibody of the present invention that does not bind to the secreted-form of Muc17.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: October 1, 2013
    Assignee: Forerunner Pharma Research Co., Ltd.
    Inventor: Kiyotaka Nakano
  • Publication number: 20130217860
    Abstract: The present invention relates generally to methods for preparing polyethylene glycol (“PEG”) conjugated hemoglobin (“Hb”) using reduced reactant ratios. More specifically, the present invention relates to methods for preparing PEG conjugated Hb (“PEG-Hb”) with enhanced yield and purity.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 22, 2013
    Applicant: SANGART, INC.
    Inventors: Ashok Malavalli, Kim D. Vandegriff
  • Publication number: 20130216479
    Abstract: Site-specific modifications of proteins at their N-termini are provided. In particular, a chemical modification of proteins at their N-termini via a transamination reaction to form homogeneous adducts such as, the corresponding oxime derivatives is provided. Methods of making and using the adducts in radio-labelling, molecular imaging applications, and treatment of disorders such as cancer, Crohn's disease, arthritis, atherothrombosis and plaque rupture are also provided.
    Type: Application
    Filed: April 1, 2013
    Publication date: August 22, 2013
    Inventors: Alexander Krantz, Peng Yu
  • Publication number: 20130177641
    Abstract: While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 11, 2013
    Applicant: Vindico NanoBio Technology Inc.
    Inventor: P. Peter Ghoroghchian
  • Publication number: 20130096210
    Abstract: The disclosure relates to metal organic frameworks or isoreticular metal organic frameworks, methods of production thereof, and methods of use thereof.
    Type: Application
    Filed: October 12, 2012
    Publication date: April 18, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
  • Publication number: 20130095551
    Abstract: A method for changing conformation of globular proteins is provided. The method controls the concentration of the globular proteins and the adsorption time of the globular proteins from the aqueous solution to the air/liquid interface, so that the main conformation of the globular proteins in a protein monolayer can be changed into ?-sheet or ?-helix. Meanwhile, the protein monolayer having the conformation of ?-sheet or ?-helix can be vertically deposited and transferred onto a substrate for various applications according to needs. The present invention can change three-dimensional structures of biological molecules and remain original functions thereof without additionally using any physical/chemical treatment to change the conformation of the globular proteins.
    Type: Application
    Filed: May 24, 2012
    Publication date: April 18, 2013
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Yuh-lang Lee, Ke-hsuan Wang
  • Publication number: 20130091604
    Abstract: A promoter for transformation of a plant, in particular an aboveground organ specific promoter, a recombinant plant expression vector including the promoter, a method of producing target protein using the recombinant plant expression vector, target protein produced by the method, a method of producing a transformed plant using the recombinant plant expression vector, a transformed plant produced by the same, and a seed of the plant.
    Type: Application
    Filed: October 8, 2012
    Publication date: April 11, 2013
    Applicant: MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATI
    Inventor: MYONGJI UNIVERSITY INDUSTRY AND ACADE
  • Publication number: 20130065250
    Abstract: The present invention relates to a kit and a probe for detecting porous dental hydroxyapatite, comprising a protein capable of binding porous dental hydroxyapatite or a detector thereof. The invention also relates to a method for detecting a condition involving porous dental hydroxyapatite comprising detecting in or on a tooth or a sample of the tooth of a subject a protein bound to porous dental hydroxyapatite. The invention also relates to methods for detecting a hypomineralisation developmental dental defect or detecting intact and/or broken MIH enamel, and to a kit and method for removing a protein bound to porous dental hydroxyapatite.
    Type: Application
    Filed: March 18, 2011
    Publication date: March 14, 2013
    Inventors: Michael James Hubbard, Jonathan Edward Mangum
  • Patent number: 8383604
    Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 26, 2013
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Stuart H. Orkin, Vijay G. Sankaran
  • Publication number: 20130041134
    Abstract: The present invention relates generally to methods for preparing polyethylene glycol maleimide (“PEG-Mal”). More specifically, the present invention relates to methods for synthesizing desired molecular weight PEG-Mal by direct ethoxylation of N-(2-hydroxyethyl)maleimide under specific reaction conditions.
    Type: Application
    Filed: November 2, 2010
    Publication date: February 14, 2013
    Applicant: SANGART ,INC.
    Inventors: John R. Handley, Jonathon B. McKannan
  • Publication number: 20130029396
    Abstract: The present disclosure relates to a multifunctional biomemory device in which a protein having a redox potential substituted with a metal ion is directly immobilized on a substrate. The present disclosure provides an operating method in which the redox state of the protein is controlled by applying three different potentials. The present disclosure provides a biomemory device in which the metal ion of a metalloprotein is substituted to allow for artificial control of the redox potential. The present disclosure provides a new-concept biomemory device as an information storage device based on the principle of electron transfer of a naturally occurring biomolecule.
    Type: Application
    Filed: February 24, 2012
    Publication date: January 31, 2013
    Applicant: Industry-University Cooperation Foundation Sogang University
    Inventors: Jeong Woo Choi, Taek Lee, Jun Hong Min
  • Patent number: 8329875
    Abstract: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 11, 2012
    Assignee: The University Of Liverpool
    Inventors: Roger Barraclough, Dong Liu Barraclough, Philip Rudland
  • Publication number: 20120269895
    Abstract: A polyion Complex (PIC) polymeric micelle is formed by interaction between a bioactive protein and a dendritic block copolymer of opposite charge. The conventional low stability of PIC micelles with bioactive proteins vis-à-vis ionic strength is offset by the stability provided by the dendritic block. The overall process for preparing the micelles is facilitated by the simplicity of the drendritic block copolymer synthesis.
    Type: Application
    Filed: July 22, 2010
    Publication date: October 25, 2012
    Applicant: Universidade De Santiago De Compostela
    Inventors: Ana Sousa Herves, Eduardo Fernandez Megia, Ricardo Riguera Vega
  • Patent number: 8273857
    Abstract: The present invention describes neuroprotective and multifunctional intra- and inter-molecular redox coupled polynitroxylated pegylated carboxy hemoglobins as high therapeutic index agents for un-met medical needs or diseases, which require acute or chronic alleviation of oxidative stress and correction of inadequate blood flow resulting from physical injury, ischemia, reperfusion injury, and inflammation injury in either or both pre-hospital and in-hospital transfusion and critical care medicine. These hemoglobins are triple-modified with a focus on therapeutic activities rather than oxygen carrying ability.
    Type: Grant
    Filed: September 22, 2010
    Date of Patent: September 25, 2012
    Inventors: Jen-Chang Hsia, Li Ma
  • Publication number: 20120213732
    Abstract: This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Therapure Biopharma Inc.
    Inventors: J. Gordon Adamson, David Bell, Nancy Ng, Petrus Biessels
  • Publication number: 20120178637
    Abstract: Methods for classifying a test sample as indicative of Alzheimer's disease use protein and peptide biomarkers that are differentially expressed in the cerebral spinal fluid (CSF) of subjects with Alzheimer's disease relative to age-matched controls. The methods also use protein and peptide signatures indicative of Alzheimer's disease. Microarrays and kits for detecting the protein and peptide biomarkers in CSF samples can be used to classify Alzheimer's disease state from test samples.
    Type: Application
    Filed: July 7, 2010
    Publication date: July 12, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Viswanath Devanarayan, Melanie Joy Patterson, Jeffrey F. Waring, David Witte
  • Patent number: 8198409
    Abstract: A mutant of the polypeptide Protein A, wherein immunoglobulin binding properties can be altered by changing temperature under the conditions of pH 5-9, below 60° C. The use of the mutant Protein A include the use thereof as a ligand coupled to an affinity chromatography support for the purification of immunoglobulins by affinity chromatography, wherein the immunoglobulins is eluted by changing temperature and thereby the conformation of the mutant Protein A.
    Type: Grant
    Filed: May 18, 2008
    Date of Patent: June 12, 2012
    Assignee: Nomadic Bioscience Co., Ltd.
    Inventor: Satoshi Sato